EP4565213A1 — Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate
Assigned to Medichem SA · Expires 2025-06-11 · 1y expired
What this patent protects
The present invention provides solid oral immediate-release formulations of ruxolitinib hemifumarate (Compound II) which show the same or higher solubility than the commercial tablets of ruxolitinib phosphate. These novel solid oral immediate-release formulations can be obtained …
USPTO Abstract
The present invention provides solid oral immediate-release formulations of ruxolitinib hemifumarate (Compound II) which show the same or higher solubility than the commercial tablets of ruxolitinib phosphate. These novel solid oral immediate-release formulations can be obtained by a process which comprises wet granulation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.